Site Editor

Jennifer R. Brown, MD, PhD


Novel BTK Inhibitor Alone or in Combination With Ublituximab and Umbralisib in CLL

By: Lauren Harrison, MS
Posted: Friday, February 4, 2022

TG-1701, a novel, irreversible Bruton’s tyrosine kinase inhibitor, appears to be both safe and active when used alone and in combination with the anti-CD20 monoclonal antibody ublituximab and the PI3Kδ inhibitor umbralisib among patients with chronic lymphocytic leukemia (CLL). The results of this phase I study were presented by Chan Yoon Cheah, MBBS, DMSc, of the University of Western Australia in Crawley, Australia, at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 1549).  

This study enrolled 142 patients with either CLL or non-Hodgkin lymphoma. Patients were treated with TG-1701 monotherapy (n = 106) or TG-1701 plus ublituximab and umbralisib (n = 36), with dose escalation of TG-1701 as tolerated. Patients were treated until disease progression, unacceptable toxicity, or patient/provider decision to withdraw.

In the monotherapy CLL-specific cohorts, 40 patients could be evaluated for safety and 39, for efficacy. The overall response rate was 97%, with consistent response rates among all subgroups. In addition, 19 patients were evaluable for safety and efficacy of TG-1701 plus ublituximab and umbralisib. The overall response rate was 84%, and 17 other patients were awaiting postbaseline assessment. The median duration of response has not yet been reached in either cohort.

The most common treatment-emergent adverse events in the monotherapy group were elevated liver transaminase levels (18% all grades), diarrhea (15%), and neutropenia (13%). One patient had an adverse event leading to a dose reduction. There were no cases of atrial fibrillation, major bleeding, or ventricular tachyarrhythmia in the CLL cohorts.

In the combination-therapy group, the most common any-grade treatment-emergent adverse events were diarrhea (53%), contusion (42%), nausea (37%), hypertension (32%), increased transaminase levels (32%), and fatigue (32%). The sole grade 3 or 4 adverse event that occurred with a high frequency was an elevated liver transaminase level (21%). One patient in this group underwent dose reduction secondary to adverse events, and four patients discontinued at least one of the study drugs.

Disclosure: For a full list of authors’ disclosures, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.